CME Group Förvaltning
Förvaltning kriterier kontrolleras 3/4
CME Group VD är Terry Duffy, utsedd i Nov 2016, har en mandatperiod på 9.5 år. totala årliga ersättningen är $ 23.39M, bestående av 8.5% lön 91.5% bonusar, inklusive företagsaktier och optioner. äger direkt 0.025% av företagets aktier, värda $ 26.08M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 9.5 år respektive 17.9 år.
Viktig information
Terry Duffy
Verkställande direktör
US$23.4m
Total ersättning
| VD-lön i procent | 8.55% |
| Anställning som VD | 9.5yrs |
| Ägande av VD | 0.03% |
| Ledningens genomsnittliga anställningstid | 9.5yrs |
| Styrelsens genomsnittliga mandatperiod | 17.9yrs |
Senaste uppdateringar av ledningen
Recent updates
CME: Volatile Street Views And New Futures Will Shape Trading Mix
Analysts have nudged their fair value estimate for CME Group down to $308.20 from $311.67, reflecting slightly softer revenue growth assumptions and a higher discount rate, partly balanced by a higher projected profit margin and a modestly lower future P/E, in line with the mix of recent price target trims and increases across the Street. Analyst Commentary Recent Street research on CME Group has been active on both sides, with several firms adjusting price targets and ratings in different directions.CME Group Q1 Earnings Show Strength, But The Stock Still Looks Expensive
Apr 23CME: Volatility And New Contracts Will Shape Rare Earths And Crypto Volumes
The updated analyst price target for CME Group has moved higher by about $5 to $311.67. This change reflects analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a marginally higher future P/E multiple, even as they factor in a small trim to projected profit margins.CME: Volatility And New Contracts Will Shape Rare Earths And Volume Mix
Analysts have made a modest upward adjustment to the CME Group fair value estimate to about $307 from roughly $305, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin, and future P/E following a mix of recent rating changes and price target tweaks across the Street. Analyst Commentary Recent research on CME Group reflects a mixed but generally balanced backdrop, with several firms adjusting ratings and price targets in different directions.CME: Volatility And New Contracts Will Shape Rare Earths And Clearing Outlook
Our analyst price target for CME Group has moved modestly higher to $305.21 from $299.29, as analysts factor in slightly stronger modeled revenue growth and profitability. This is partially offset by a more conservative future P/E assumption and mixed views on volume drivers across product lines.CME: Volatility And New Contracts Will Shape Futures And Clearing Outlook
The analyst price target for CME Group edges higher to $232, with recent updates reflecting analysts' focus on firmer commodities volumes, as well as a more expense conscious outlook in their refreshed earnings models. Analyst Commentary Recent Street research around CME Group reflects a mix of optimism on volumes and earnings power, alongside caution on valuation and the cost base.CME: Volatility And Prediction Markets Will Guide Futures And Clearing Expansion Outlook
The updated analyst price target for CME Group edges higher to about US$297 from roughly US$290, reflecting analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a similar future P/E multiple despite a slightly lower profit margin input. Analyst Commentary Street research on CME Group in recent sessions centers on a cluster of revised price targets and at least one rating change, with several bullish analysts lifting their targets by varying dollar amounts and one major bank fine tuning its view in both directions over a short time frame.CME: Volatility And Prediction Markets Will Shape Futures Activity Outlook
The analyst price target for CME Group is now US$290.40, a move of about US$2 from the prior US$288.33, as analysts factor in slightly different assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E following mixed recent research that includes both a modest target cut and an upgrade linked to a tilt toward volatility. Analyst Commentary Recent research on CME Group reflects a mix of optimism and caution, with one firm trimming its price target slightly and another upgrading the stock on what it sees as a better setup for volatility related trading activity.CME: Fee Moat And Prediction Markets Will Shape Futures Activity Outlook
Narrative Update: CME Group CME Group's fair value estimate has edged up by about $1 to roughly $288 per share, as analysts cite the company's strong futures and options moat, a higher price target range of up to $314, and interest in its role within prediction markets as key supports for the updated outlook. Analyst Commentary Recent Street research has been generally constructive on CME Group, with several bullish analysts adjusting their price targets higher and highlighting the company's futures and options franchise as a key support for valuation.CME: Fee Resilience And Prediction Markets Will Balance Lower Volatility Risks
Analysts have nudged their average price target on CME Group modestly higher, to approximately $287 from about $286, citing the company’s resilient fee-based revenue mix, strong competitive moat in futures and options, and supportive demand signals from prediction market partnerships despite some conflicting views on near term volume volatility. Analyst Commentary Recent Street research presents a mixed but generally constructive view on CME Group, with upward moves in price targets tempered by concerns around volume sensitivity and valuation risk if volatility normalizes.CME: Fee Resilience And New Prediction Markets Will Help Navigate Volatility
Analysts have raised their fair value estimate for CME Group by about $1 to roughly $286 per share, citing the company’s resilient clearing and transaction fee driven revenue base, modestly higher long term growth expectations, and a reinforced competitive moat highlighted in recent target revisions across the Street. Analyst Commentary Street research on CME Group reflects a wide range of views on valuation and execution, with recent target changes clustering around expectations for resilient fee income but diverging on the sustainability of growth and the impact of lower volatility.CME: Revenue Resilience And New Ventures Will Balance Volatility Risks Ahead
The average analyst price target for CME Group was raised by approximately $3 to $285, as analysts point to the firm's resilient revenue streams and strong market position amid continued macroeconomic uncertainty. Analyst Commentary Recent analyst activity reflects a mix of optimism and caution regarding CME Group's performance and outlook, particularly as the firm navigates shifting macroeconomic and market conditions.CME: More Market Volatility Equals More Demands - Initiating With Strong Buy
Apr 27CME Group At A New All-Time High - Valuation Concerns Justified?
Mar 27CME Group: High Quality With Good Dividend Yield
Feb 18CME Group: Exchanges And Data Will Keep Growing, And So Could Its Dividend
Dec 30CME Group's Dominance Challenged By Now Operational FMX?
Dec 13Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$4b |
| Dec 31 2025 | US$23m | US$2m | US$4b |
| Sep 30 2025 | n/a | n/a | US$4b |
| Jun 30 2025 | n/a | n/a | US$4b |
| Mar 31 2025 | n/a | n/a | US$4b |
| Dec 31 2024 | US$24m | US$2m | US$3b |
| Sep 30 2024 | n/a | n/a | US$3b |
| Jun 30 2024 | n/a | n/a | US$3b |
| Mar 31 2024 | n/a | n/a | US$3b |
| Dec 31 2023 | US$23m | US$2m | US$3b |
| Sep 30 2023 | n/a | n/a | US$3b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$3b |
| Dec 31 2022 | US$23m | US$2m | US$3b |
| Sep 30 2022 | n/a | n/a | US$3b |
| Jun 30 2022 | n/a | n/a | US$3b |
| Mar 31 2022 | n/a | n/a | US$3b |
| Dec 31 2021 | US$23m | US$2m | US$3b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$2b |
| Dec 31 2020 | US$16m | US$2m | US$2b |
| Sep 30 2020 | n/a | n/a | US$2b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$12m | US$2m | US$2b |
Ersättning vs marknad: Terry s total kompensation ($USD 23.39M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 14.54M ).
Ersättning vs inkomst: Ersättningen från Terry har varit i linje med företagets resultat under det senaste året.
VD OCH KONCERNCHEF
Terry Duffy (67 yo)
9.5yrs
Anställning
US$23,394,854
Kompensation
Mr. Terrence A. Duffy, also known as Terry, has been Chief Executive Officer and Chairman at CME Group, the world’s leading derivatives marketplace since November 15, 2016. Mr. Duffy is the Chief Executive...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Chairman & CEO | 9.5yrs | US$23.39m | 0.025% $ 26.1m | |
| President & CFO | 3.1yrs | US$4.75m | 0.0066% $ 6.9m | |
| Chief Information Officer | 4.3yrs | US$3.38m | 0.0065% $ 6.8m | |
| Senior MD & Global Head of Commodities Markets | 16.6yrs | US$3.39m | 0.0086% $ 9.0m | |
| Senior MD & Chief Commercial Officer | 19.3yrs | US$3.38m | 0.0083% $ 8.7m | |
| Senior MD | 1.5yrs | inga uppgifter | 0.0038% $ 4.0m | |
| MD & Chief Accounting Officer | 11.3yrs | inga uppgifter | 0.0070% $ 7.3m | |
| Managing Director of Investor Relations | no data | inga uppgifter | inga uppgifter | |
| Senior MD & General Counsel | 3.6yrs | inga uppgifter | 0.0020% $ 2.1m | |
| Senior Managing Director of Corporate Marketing & Communications | 19.3yrs | inga uppgifter | inga uppgifter | |
| Senior MD & Chief Human Resources Officer | 18.8yrs | inga uppgifter | 0.0092% $ 9.6m | |
| Chief Transformation Officer | 6.3yrs | inga uppgifter | 0.0052% $ 5.4m |
9.5yrs
Genomsnittlig anställningstid
57yo
Genomsnittlig ålder
Erfaren ledning: CME s ledningsgrupp är erfaren och erfaren ( 9.5 års genomsnittlig anställning).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Chairman & CEO | 31.3yrs | US$23.39m | 0.025% $ 26.1m | |
| Independent Director | 17.8yrs | US$335.67k | 0.00074% $ 771.8k | |
| Independent Director | 32.3yrs | US$288.50k | 0.0069% $ 7.2m | |
| Independent Director | 29.3yrs | US$311.25k | 0.072% $ 75.6m | |
| Independent Director | 26.3yrs | US$301.25k | 0.019% $ 20.1m | |
| Independent Director | 6yrs | US$269.25k | 0.012% $ 12.4m | |
| Independent Director | 18.8yrs | US$337.84k | 0.0016% $ 1.7m | |
| Independent Director | 18yrs | US$316.25k | 0.0031% $ 3.2m | |
| Independent Director | 8yrs | US$312.25k | 0.035% $ 36.4m | |
| Independent Director | 7yrs | US$301.25k | 0.0012% $ 1.2m | |
| Independent Director | 7yrs | US$313.25k | 0.0010% $ 1.0m | |
| Independent Director | 6yrs | US$292.84k | 0.0011% $ 1.2m |
17.9yrs
Genomsnittlig anställningstid
67.5yo
Genomsnittlig ålder
Erfaren styrelse: CME s styrelse är rutinerade och erfaren ( 17.9 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/01 13:58 |
| Aktiekurs vid dagens slut | 2026/05/01 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
CME Group Inc. bevakas av 34 analytiker. 13 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Stephen Biggar | Argus Research Company |
| Benjamin Budish | Barclays |
| Roger Freeman | Barclays |